A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University of Chicago, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Samsung Medical Center, Sungkyunkwan University, Université de Lyon, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Cliniques Universitaires Saint-Luc, UCLouvain, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, University of Colorado Denver, National and Kapodistrian University of Athens, University General Hospital Attikon
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2789592300